Literature DB >> 18390833

Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.

Jing Huang1, Pawel M Kaminski, John G Edwards, Albert Yeh, Michael S Wolin, William H Frishman, Michael H Gewitz, Rajamma Mathew.   

Abstract

Monocrotaline (MCT)-induced pulmonary artery hypertension (PAH) in rats is preceded by an inflammatory response, progressive endothelial cell membrane disruption, reduction in the expression of caveolin-1, and reciprocal activation of STAT3 (PY-STAT3). Superoxide and NF-kappaB have been implicated in PAH. To evaluate the role of caveolin-1, PY-STAT3 activation, and superoxide in PAH, MCT-injected rats were treated daily with pyrrolidine dithiocarbamate (PDTC; starting on days 1, 3, and 14 x 2 wk), an inhibitor of inflammation and NF-kappaB activation. Hemodynamic data, the expression of inhibitory (I)-kappaBalpha, caveolin-1, and Tie2 (a membrane protein), activation of PY-STAT3 and NF-kappaB, and superoxide chemiluminescence were examined. Rats developed progressive PAH at 2 wk post-MCT. There was progressive reduction in the expression of caveolin-1, Tie2, and activation of PY-STAT3 in the lungs. Reduction in I-kappaBalpha expression was present at 2 and 4 wk post-MCT. Superoxide chemiluminescence and NF-kappaB activation were observed only at 2 wk post-MCT and both decreased by 4 wk post-MCT despite progressive PAH. PDTC (starting on days 1 and 3) rescued caveolin-1 and Tie2, reversed MCT-induced PY-STAT3 activation, and attenuated PAH. In addition, PDTC restored I-kappaBalpha expression and reduced superoxide chemiluminescence at 2 wk but did not inhibit NF-kappaB activation despite attenuation of PAH. PDTC had no effect on established PAH. Increased superoxide chemiluminescence and NF-kappaB activation appear to be a transient phenomenon in the MCT model. Thus the disruption of endothelial cell membrane integrity resulting in caveolin-1 loss and reciprocal activation of PY-STAT3 plays a key role in the MCT-induced PAH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390833      PMCID: PMC2441448          DOI: 10.1152/ajplung.00069.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  48 in total

Review 1.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.

Authors:  T Hirano; K Ishihara; M Hibi
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 2.  Lipid rafts and signal transduction.

Authors:  K Simons; D Toomre
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

3.  Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation.

Authors:  Salvatore Cuzzocrea; Prabal K Chatterjee; Emanuela Mazzon; Laura Dugo; Ivana Serraino; Domenico Britti; Giuseppe Mazzullo; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

4.  Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs.

Authors:  Rajamma Mathew; Ning Yuan; Louis Rosenfeld; Michael H Gewitz; Ashok Kumar
Journal:  Heart Dis       Date:  2002 May-Jun

5.  Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway.

Authors:  Christopher C Sullivan; Lingling Du; Danny Chu; Augustine J Cho; Masakuni Kido; Paul L Wolf; Stuart W Jamieson; Patricia A Thistlethwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-25       Impact factor: 11.205

6.  Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.

Authors:  You-Yang Zhao; Yang Liu; Radu-Virgil Stan; Lian Fan; Yusu Gu; Nancy Dalton; Po-Hsien Chu; Kirk Peterson; John Ross; Kenneth R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation.

Authors:  Brian S Zuckerbraun; Carol A McCloskey; Raja S Mahidhara; Peter K M Kim; Bradley S Taylor; Edith Tzeng
Journal:  J Vasc Surg       Date:  2003-10       Impact factor: 4.268

8.  Cellular apoptosis is associated with increased caveolin-1 expression in macrophages.

Authors:  Peter Gargalovic; Ladislav Dory
Journal:  J Lipid Res       Date:  2003-06-01       Impact factor: 5.922

9.  Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway.

Authors:  Timothy E Peterson; Maria E Guicciardi; Rajiv Gulati; Laurel S Kleppe; Cheryl S Mueske; Martina Mookadam; Grzegorz Sowa; Gregory J Gores; William C Sessa; Robert D Simari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-19       Impact factor: 8.311

Review 10.  Inflammation in pulmonary arterial hypertension.

Authors:  P Dorfmüller; F Perros; K Balabanian; M Humbert
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

View more
  26 in total

1.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

2.  Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.

Authors:  Jing Huang; John H Wolk; Michael H Gewitz; James E Loyd; James West; Eric D Austin; Rajamma Mathew
Journal:  World J Cardiol       Date:  2015-10-26

3.  Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.

Authors:  Philip M Bauer; Eileen M Bauer; Natasha M Rogers; Mingyi Yao; Monica Feijoo-Cuaresma; Joseph M Pilewski; Hunter C Champion; Brian S Zuckerbraun; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2012-01-02       Impact factor: 10.787

Review 4.  The Search for Disease-Modifying Therapies in Pulmonary Hypertension.

Authors:  Chen-Shan Chen Woodcock; Stephen Y Chan
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-02-17       Impact factor: 2.457

5.  Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of rapamycin complex 1 regulation and global protein translation.

Authors:  Shaoming Song; Kotb Abdelmohsen; Yongqing Zhang; Kevin G Becker; Myriam Gorospe; Michel Bernier
Journal:  J Pharmacol Exp Ther       Date:  2011-09-13       Impact factor: 4.030

Review 6.  Caveolins and lung function.

Authors:  Nikolaos A Maniatis; Olga Chernaya; Vasily Shinin; Richard D Minshall
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension.

Authors:  Wei Wang; Yu-Lin Wang; Xiao-Ying Chen; Yu-Tang Li; Wei Hao; You-Peng Jin; Bo Han
Journal:  Mol Biol Rep       Date:  2011-03-23       Impact factor: 2.316

8.  Caveolin 1 inhibits HIV replication by transcriptional repression mediated through NF-κB.

Authors:  Xiao Mei Wang; Peter E Nadeau; Shanshan Lin; Jeffrey R Abbott; Ayalew Mergia
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

Review 9.  Reactive oxygen species and antioxidants in pulmonary hypertension.

Authors:  Chi-Ming Wong; Geetanjali Bansal; Ludmila Pavlickova; Lucia Marcocci; Yuichiro J Suzuki
Journal:  Antioxid Redox Signal       Date:  2012-07-11       Impact factor: 8.401

Review 10.  Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1.

Authors:  Rajamma Mathew
Journal:  World J Cardiol       Date:  2014-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.